Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment

A vascular endothelium and growth factor technology, applied in cardiovascular system diseases, medical preparations containing active ingredients, peptide/protein components, etc. ECM degradation and other issues

Inactive Publication Date: 2019-01-04
INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, not all patients with myocardial infarction can be effectively treated in the acute phase, leading to potential myocardial cell death and degradation of myocardial extracellular matrix, leading to old myocardial infarction
Although percutaneous transluminal coronary angioplasty (VTCA) and coronary artery bypass grafting (CABG) can partially restore myocardial function in patients with old myocardial infarction by increasing blood supply, it is difficult to compensate for necrotic cardiomyocytes and degraded cardiomyocytes. It is reported that more than half of heart transplant patients come from patients with old myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment
  • Application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment
  • Application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1, Preparation of CT-VEGF and Detection of Ischemic Myocardial Targeting Ability

[0111] The CT-VEGF provided by the present invention is a protein whose amino acid sequence is SEQ ID No.1 in the sequence listing, and its coding sequence is SEQ ID No.2 in the sequence listing.

[0112] Wherein, the 1-166th amino acid of SEQ ID No.1 is the sequence of vascular endothelial growth factor, and its coding sequence is the 1-498th nucleotide of SEQ ID No.2; The 184th amino acid is the sequence of the collagen binding region CT, and its coding sequence is the 532-552th nucleotide of SEQ ID No.2; the 187th-192th amino acid of SEQ ID No.1 is the sequence of the His tag, which encodes The sequence is 559-576 nucleotides of SEQ ID No.2.

[0113] 1. Preparation of CT-VEGF

[0114] 1. Preparation of recombinant vector and recombinant bacteria

[0115] The sequence between the XbaI and XhoI recognition sequences of the pET28a vector was replaced with the DNA fragment shown...

Embodiment 2

[0135] Example 2, CT-VEGF can be used to treat old myocardial infarction

[0136] The experiment was repeated three times, and the operation steps of each repeated experiment were as follows:

[0137] Fifteen Bama pigs were selected, and the left anterior descending coronary artery was ligated to prepare a pig model of old myocardial infarction. One month later, the CT-VEGF solution, VEGF solution and PBS (as a control, control) of Example 1 were injected around the ischemic myocardium after thoracotomy for the second time ( figure 2 ), the injection volume was 1ml, and five pigs were treated with each liquid. Heart function was detected by echocardiography and nuclear magnetic resonance at 1 month, 3 months, 6 months and 12 months after injection. Pathological testing was performed after the samples were taken, and the correlation analysis between pathological testing and cardiac function testing was completed.

[0138] 1. Short-term (3-month) effect evaluation of CT-VEGF...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment. In the application, the collagen targeted vascular endothelial growth factors are fused proteins obtained by fusing collagen binding regions at the ends N and / or C of the vascular endothelial growth factors, the vascular endothelial growth factors are proteins shownfrom the first site to the 166th site with the amino acid sequence of SEQ ID No.1, and the collagen binding regions are proteins shown from the 178th site to the 184th site with the amino acid sequence of SEQ ID No.1. It is shown through experiments that the collagen targeted vascular endothelial growth factors have the capacity of being combined with a cell epimatrix and can be specifically combined with an ischemia cardiomyocyte epimatrix, the myocardial ischemic injury repairing effect is improved, the side effects of VEGF high-dosage medicine application can be avoided, and the collagen targeted vascular endothelial growth factors can be used for treating the old myocardial infarction.

Description

technical field [0001] The invention relates to the application of collagen targeting vascular endothelial growth factor in the treatment of old myocardial infarction in the field of biotechnology. Background technique [0002] Ischemic heart disease and its secondary myocardial injury are a serious threat to human health. The fundamental reason is that myocardial cell necrosis and myocardial extracellular matrix degradation are caused by insufficient blood supply to myocardial tissue. For the treatment of acute myocardial infarction, timely improvement of myocardial blood perfusion and restoration of local myocardial function through drugs or surgery is the key to its treatment. However, not all patients with myocardial infarction can be effectively treated in the acute phase, leading to potential myocardial cell death and degradation of myocardial extracellular matrix, leading to old myocardial infarction. Although percutaneous transluminal coronary angioplasty (VTCA) and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P9/10
CPCA61K38/1866
Inventor 戴建武陈冰施春英
Owner INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com